Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Inclusion criteria for patients: 1. Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides 2. Age ≥18 years 3. Stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry: 1. Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors 2. Cyclophosphamide (intravenous pulses or daily oral) 3. B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab) 4. Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab 5. Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab 6. Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab 7. The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib 4. Female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination 5. Willing to comply with all study procedures Exclusion criteria for patients: 1. Active infection, including upper respiratory tract infection 2. Active HZ infection 3. Active untreated tuberculosis 4. HIV infection 5. History of HZ or varicella vaccination in the past 6. History of allergy to any vaccines 7. Patients who are pregnant or plan to become pregnancy within one year of study entry 8. Lactating women 9. Patients who cannot give a written consent (mentally incapable or illiterate)